Human stem cell-based models for studying autism spectrum disorder-related neuronal dysfunction

• Published in: Molecular autism Vol. 11; no. 1; p. 99
• Main Authors: Cheffer, Arquimedes, Flitsch, Lea Jessica, Krutenko, Tamara, Röderer, Pascal, Sokhranyaeva, Liubov, Iefremova, Vira, Hajo, Mohamad, Peitz, Michael, Schwarz, Martin Karl, Brüstle, Oliver
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 11.12.2020; BioMed Central; BMC
• Subjects: Animals; Autism; Autism spectrum disorder; Autism Spectrum Disorder - pathology; Autism Spectrum Disorder - physiopathology; Brain; Brain organoids; Cell reprogramming; Cellular Reprogramming - genetics; Humans; In vitro differentiation; Induced pluripotent stem cells; Induced Pluripotent Stem Cells - pathology; Models, Biological; Mutation; Neurodevelopmental disorders; Neuronal connectivity; Neurons - pathology; Nuclear reprogramming; Organoids - pathology; Review; Stem cells; Germany; Cell reprogramming; Induced pluripotent stem cells; Brain organoids; Autism spectrum disorder; In vitro differentiation; Neuronal connectivity
• ISSN: 2040-2392; 2040-2392
• DOI: 10.1186/s13229-020-00383-w

The controlled differentiation of pluripotent stem cells (PSCs) into neurons and glia offers a unique opportunity to study early stages of human central nervous system development under controlled conditions in vitro. With the advent of cell reprogramming and the possibility to generate induced pluripotent stem cells (iPSCs) from any individual in a scalable manner, these studies can be extended to a disease- and patient-specific level. Autism spectrum disorder (ASD) is considered a neurodevelopmental disorder, with substantial evidence pointing to early alterations in neurogenesis and network formation as key pathogenic drivers. For that reason, ASD represents an ideal candidate for stem cell-based disease modeling. Here, we provide a concise review on recent advances in the field of human iPSC-based modeling of syndromic and non-syndromic forms of ASD, with a particular focus on studies addressing neuronal dysfunction and altered connectivity. We further discuss recent efforts to translate stem cell-based disease modeling to 3D via brain organoid and cell transplantation approaches, which enable the investigation of disease mechanisms in a tissue-like context. Finally, we describe advanced tools facilitating the assessment of altered neuronal function, comment on the relevance of iPSC-based models for the assessment of pharmaceutical therapies and outline potential future routes in stem cell-based ASD research.